

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

STEFFEN HASENZAHN, *et al.*

Serial No.: 10/530,326

Filed: April 5, 2005

For: PHARMACEUTICAL AND COSMETIC  
FORMULATIONS

Conf. No.: 4709

Art Unit: 1611

Examiner: Rachael E. WELTER

Atty. Dckt: 032301.608 (formerly 39509.213934)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Listed on the accompanying Form SB08 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. § 1.56, 1.97 and 1.98. Copies of the references are enclosed. Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that an exhaustive search has been made, or that there does not exist information more material to the examination of the present patent application. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will review art of record in all 35 U.S.C. § 120 priority documents.


- ☒ The Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1); or
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56 (c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2); or
- ☒ c. The amount of **\$180.00** in payment of the fee under 37 C.F.R. § 1.17(p) is being made via:

- ☐ Check no. \_\_\_\_\_
- ☐ **Deposit Account No. 02-4300**, Attorney Docket No. **032301.608** (formerly 39509.213934).
- ☒ A credit card online.

It is respectfully requested that the Examiner initial and return a copy of the enclosed SB08, and to indicate in the official file wrapper of this patent application that the documents have been considered.

The Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to our **02-4300**, Attorney Docket No. **032301.608** (formerly 39509.213934).

Respectfully submitted,



Thomas G. Wiseman

Registration No. 35,046

Date: May 11, 2009

SMITH, GAMBRELL & RUSSELL, LLP  
1130 Connecticut Ave., NW, #1130  
Washington, D.C. 20036  
Telephone: (202) 263-2617  
Fax: (202) 263-4329  
twiseman@sgrlaw.com